Rhythm Pharmaceuticals Announces FDA Approval Of IMCIVREE® (Setmelanotide) For Patients As Young As 2 Years Old
(MENAFN- GlobeNewsWire - Nasdaq) BOSTON, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, …